They are classified as glucagon-like peptide 1 (GLP-1) agonists and, in addition to diabetes treatment, also demonstrate ...
The Trulicity pen -- an injectable drug for patients to manage their type 2 diabetes -- has been around for quite some time.
Full year sales for Trulicity in 2016 were approaching $1 billion, compared with just over $3 billion for Victoza. The 40-week SUSTAIN 7 trial investigated the efficacy and safety of 0.5 mg ...